Loading
Pembrolizumab shrank tumours in about a third of patients with mismatch repair-deficient cancers of many different organs, with responses that often lasted years; the pancreatic cancer group responded less often than most. It is the trial behind the tissue-agnostic approval for MSI-high cancer.
Phase 2 basket study of pembrolizumab 200 mg every three weeks in 233 patients with previously treated advanced non-colorectal MSI-high or mismatch repair-deficient cancer across 27 tumour types, endometrial, gastric, cholangiocarcinoma and pancreatic cancer among the largest cohorts.
The objective response rate was about 34 percent with a median duration of response not reached, median progression-free survival 4.1 months and median overall survival 23.5 months. In the 22 patients with pancreatic cancer the response rate was about 18 percent and median overall survival about 4 months, the lowest of the major cohorts. The data supported the FDA's tissue-agnostic approval of pembrolizumab for MSI-high cancer.
Every pancreatic cancer should be tested for mismatch repair deficiency because the 1 percent who have it can receive pembrolizumab, but responses in pancreatic cancer are less frequent and less durable than in other MSI-high cancers.
Shares KEYNOTE-158, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma.
Shares KEYNOTE-158, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma.
Shares dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), Tumour-agnostic (tissue-agnostic) approval.
Shares dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), Tumour-agnostic (tissue-agnostic) approval.
Shares Dung T. Le, Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing).
Shares Dung T. Le, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/